… ProQR Announces a Proof-of-Concept Nasal Potential Difference … the Netherlands, Sept. 14, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that … said Noreen R. Henig, MD, Chief Development Officer of ProQR. "This study is an important proof-of-concept study …
… ProQR Receives € 4.7 million in Innovation Credit from Dutch … CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … or the clinical development of a medicine or device. ProQR was awarded an Innovation credit for the QR-110 …
… ProQR Announces Presentation on QR-421a Program in … and CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … delivered by Dr. Aniz Girach, MD, chief medical officer of ProQR, on QR-421a for Usher Syndrome during the USH2019 …
… ProQR to Highlight a Growing Pipeline During a Research & … the Netherlands, March 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … at 10am ET. Daniel de Boer, Chief Executive Officer of ProQR will also take part in an analyst led fireside chat at …
… ProQR Announces Enrollment Has Started in Global Phase 1b … LEIDEN, the Netherlands, June 26, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that … said Daniel A. de Boer, Chief Executive Officer of ProQR. "Since the foundation of the company 3 years ago our …
… ProQR Announces Clearance of IND to Start Clinical Trial of … & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … said Daniel A. de Boer, Chief Executive Officer of ProQR. “QR-421a has shown promising activity in both the …
… ProQR Receives Fast Track Designation from the FDA for QR-110 … for Leber’s Congenital Amaurosis Type 10 Key Updates ProQR receives Fast Track designation by the U.S. Food and … LEIDEN, the Netherlands, May 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it …
… ProQR Announces Closing of Initial Public Offering and Full … The Netherlands, Sept. 23, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) announced today the … securities laws of any such state or jurisdiction. About ProQR We are an innovative biopharmaceutical company engaged …
Reported rapid, significant and durable improvements in vision at twelve months
Concordant improvement in key secondary outcome measures
The target registration dose of sepofarsen was well-tolerated with a favorable benefit/risk profile
Strengthens confidence